Elucidation of treatment-specific gene mutation by liquid biopsy in patients with soft tissue sarcomas

Elucidation of treatment-specific gene mutation by liquid biopsy in patients with soft tissue sarcomas - Usefullness of liquid biopsy in patients with soft tissue sarcomas

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000038273

Enrollment

Registered

2019-12-01

Start date

2019-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

advanced soft tissue sarcomas

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: advanced soft tissue sarcoma expected life expectancy more than 6 months Performance status 0-2 Informed consent obtained

Exclusion criteria

Exclusion criteria: Fresh tumor tissue could be obtained Infomed consent not obtained Performance status equal or more than 3

Design outcomes

Primary

Measure	Time frame
Identification of gene mutations to be treated	—

Countries

Japan

Contacts

Public ContactKunihiro Ikuta

Nagoya University Hospital Genome Medical Center

k-ikuta@med.nagoya-u.ac.jp052-744-1908

Outcome results